Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1191)	9/21/1998 10:05:00 PM
From: Ed Ajootian	Read Replies (2) \| Respond to of 10280

Peter, Truly an amazing day for SEPR. This stock just seems to have wings. A mere 10 months ago this drug was just in _pre-clinical trials. Whaddaya figure, this Phase III study goes all fall, then give a few months to process the data, and they announce the results in late winter & file the NDA in the spring? If so this has gotta be a world record for shortest time from preclinicals to NDA -- not even a year & a half!!! This desloratadine has almost caught up to norastemizole now. SEPR looks to be in the enviable position of having TWO blockbuster allergy drugs getting approved in the same goddam year!